BIOSCRIP, INC. (NASDAQ:BIOS) Files An 8-K Results of Operations and Financial Condition

BIOSCRIP, INC. (NASDAQ:BIOS) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.

Story continues below

On August 8, 2017, the Company issued a press release reporting its 2017 second quarter financial results (the “Original Earnings Release”), which was furnished as an exhibit to the Company’s Current Report on Form8-K filed on August 8, 2017. The Company is hereby revising the Original Earnings Release (the “Revised Earnings Release”) to replace the Schedule 5 included therein with a revised schedule that includes “Loss on Extinguishment of Debt” as a line item in the reconciliation table and revises the number of weighted-average diluted shares. No other changes to the Original Earnings Release were made. The Revised Earnings Release replaces the Original Earnings Release and has been re-posted on the Company’s website. A copy of the Revised Earnings Release is furnished as Exhibit99.1 to this Form8-K/A.

The Revised Earnings Release includes certain non-GAAP financial measures as described therein. As required by Regulation G, reconciliation between any non-GAAP financial measures presented and the most directly comparable GAAP financial measures is also provided.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

See the Exhibit Index, which is hereby incorporated by reference.

As provided in General Instruction B.2 to Form 8-K, the information furnished in Item 2.02 and in Exhibit 99.1 hereto, as it relates to the Company’s financial results for the quarter ended June 30, 2017, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section and shall not be deemed incorporated by reference into any filing of the Company with the Securities and Exchange Commission under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly provided by specific reference in such filing.

BioScrip, Inc. Exhibit
EX-99.1 2 v472765_ex99-1.htm EXHIBIT 99.1   Exhibit 99.1     BioScrip Reports Second Quarter 2017 Financial Results   -Net revenue of $218.1 million,…
To view the full exhibit click here


BioScrip, Inc. is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment. The Company operates through approximately 70 service locations in over 30 states. The Company offers home infusion services to provide clinical management services and the delivery of prescription medications. The Company provides services in coordination with, and under the direction of, the patient’s physician. The Company’s multidisciplinary team of clinicians, including pharmacists, nurses, dietitians and respiratory therapists, work with the physician to develop a plan of care suited to the patient’s specific needs. Its platform provides service capabilities to deliver clinical management services that offer patients a community-based and home-based care environment.

An ad to help with our costs